Safety, efficacy seen for Sjögren’s therapy ianalumab in pair of trials
Novartis' therapy candidate ianalumab safely and effectively eased disease activity for adults with active Sjögren's in two clinical trials.| Sjogren's Disease News
Novartis' therapy candidate ianalumab safely and effectively eased disease activity for adults with active Sjögren's in two clinical trials.| Sjogren's Disease News
Prompt treatment for Sjögren’s was found to improve recovery, and reduce the risk of recurrence, in patients who develop ischemic stroke.| Sjogren's Disease News
